Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
Location: United Kingdom, England, London
Employees: 11-50
Founded date: 2016
Investment Type: Venture Capital
Investment Stage: Series A; Series B; Series C
Portfolio 16
| Date | Name | Website | Total Raised | Location |
| 26.04.2023 | Evommune | evommune.com | $405.5M | United Sta... |
| 18.03.2019 | Imara | imaratx.com | $63M | United Sta... |
| 21.12.2017 | Aura Biosc... | aurabiosciences.com | $183M | United Sta... |
| 04.12.2017 | Atox Bio | atoxbio.com | $56.25M | United Sta... |
| 27.07.2017 | PRECITHERA... | precithera.com | $29M | - |
| 28.06.2017 | LogicBio T... | logicbio.com | $49M | United Sta... |
| 25.05.2017 | Harpoon Th... | harpoontx.com | $201.25M | United Sta... |
| 19.05.2017 | Iterum The... | iterumtx.com | $157M | - |
| - | VelosBio | velosbio.com | $195M | United Sta... |
| - | Depixus | depixus.com | $35.4M | France, Il... |
Show more
Persons 2
| Date | First Name | Last Name | Title | Location | |||
| - | Debra | Barker | Senior Ind... | - | - | - | |
| - | Tassos | Konstantin... | Managing D... | linkedin.c... | - | - | - |
News 337
Show more
Mentions in press and media 28
| Date | Title | Description |
| 22.12.2021 | Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions | SALT LAKE CITY, Dec. 22, 2021 /PRNewswire/ -- Sorriso Pharmaceuticals, a company focused on transforming anti-inflammatory antibody therapy, today announced the company has closed on a $31 million Series A financing. The round was co-led by... |
| 02.09.2021 | Arix Bioscience participates in USD90 million Series B financing for Disc Medicine | Arix Bioscience PLC (ARIX) Arix Bioscience participates in USD90 million Series B financing for Disc Medicine 02-Sep-2021 / 11:20 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible... |
| 14.06.2021 | ARIX BIOSCIENCE PLC Results of Annual General Meeting | Arix Bioscience PLC (ARIX) Results of Annual General Meeting 14-Jun-2021 / 14:55 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =---------... |
| 18.05.2021 | ARIX BIOSCIENCE PLC Notice of 2021 Annual General Meeting | Arix Bioscience PLC (ARIX) Notice of 2021 Annual General Meeting 18-May-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =-----... |
| 08.04.2021 | ARIX BIOSCIENCE PLC Arix to Present at the Proactive One2One Virtual Investor Forum | Arix Bioscience PLC Arix to Present at the Proactive One2One Virtual Investor Forum 08-Apr-2021 / 07:00 GMT/BST =---------------------------------------------------------------------------------------------------------------------- Arix Bio... |
| 09.03.2021 | ARIX BIOSCIENCE PLC Annual Results for the Twelve Months ended 31 December 2020 | Arix Bioscience PLC (ARIX) Annual Results for the Twelve Months ended 31 December 2020 09-March-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of t... |
| 08.07.2020 | ARIX BIOSCIENCE PLC Arix Bioscience Plc : - VelosBio completes $137 million Series B financing | Arix Bioscience plc VelosBio completes $137 million Series B financing LONDON, 8 July 2020: Arix Bioscience plc (“Arix”, LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today... |
| 09.04.2020 | Frederic Pla enlisted as COO at the Parker Institute; Former Alkermes exec named CMO at Seres Therapeutics | Frederic Pla Parker Institute → The Parker Institute for Cancer Immunotherapy has welcomed Frederic Pla aboard as COO. Prior to his appointment, Pla served as COO at Genomic Health. Pla has held appointments at Life Te... |
| 13.03.2020 | CureVac’s Ingmar Hoerr tells us why he returned to take on a pandemic; NGM loses a president | Ingmar Hoerr On Tuesday, Ingmar Hoerr stood up from his seat at the head of CureVac’s board of directors meeting in Frankfurt, Germany and walked out the door. For 18 years, Hoerr had led the company he founded, stewardin... |
| 10.03.2020 | Versant woos MorphoSys' ex-CSO to its booming discovery engine, with big plans for new startups | As MorphoSys celebrated the FDA’s acceptance of its first-ever BLA — complete with a priority review that could lead to a quick OK for its CD19-targeted CAR-T rival — last Monday, former CSO Markus Enzelberger was markin... |
Show more